PMID- 33118740
OWN - NLM
STAT- MEDLINE
DCOM- 20210204
LR  - 20210204
IS  - 1678-9741 (Electronic)
IS  - 0102-7638 (Print)
IS  - 0102-7638 (Linking)
VI  - 35
IP  - 5
DP  - 2020 Oct 1
TI  - Cardiac Shock Wave Therapy for Coronary Heart Disease: an Updated Meta-analysis.
PG  - 741-756
LID - 10.21470/1678-9741-2019-0276 [doi]
AB  - INTRODUCTION: The aim of this article is to study the efficacy and safety of 
      cardiac shock wave therapy (CSWT) in the treatment of coronary heart disease 
      (CAD). METHODS: A comprehensive search of electronic databases and a manual 
      search of conference papers and abstracts were performed until September 30, 
      2018. The studies using RevMan 5.3 and STATA 14.0 softwares were reviewed, and 
      meta-analyses were performed on 13 indicators, such as a six-min walking distance 
      test (6MWT), New York Heart Association (NYHA) functional class, Seattle Angina 
      Questionnaire (SAQ) score, angina class (Canadian Cardiology Society [CCS]), etc. 
      RESULTS: A total of 26 articles were included. The total patient population was 
      855, of which 781 patients were treated with CSWT. Meta-analyses indicated that 
      6MWT (mean difference [MD] 75.64, 95% confidence interval [CI] 49.03, 102.25, 
      P<0.00001) and NYHA (MD -0.70, 95% CI -0.92) in the CSWT group were comparable to 
      those in the conventional revascularization group (MD -0.70, 95% CI -0.92, -0.49, 
      P<0.00001). SAQ (MD 10.75, 95% CI 6.66, 14.83, P<0.00001), CCS (MD -0.99, 95% CI 
      -1.13, -0.84, P<0.00001), nitrate dosage (MD -1.84, 95% CI -2.77, -1.12, 
      P<0.00001), LVEF (MD 3.77, 95% CI 2.17, 5.37, P<0.00001), and SSS (MD -4.29, 95% 
      CI -5.61, -2.96, P<0.00001), SRS (MD -2.90, 95% CI -4.85, -0.95, P=0.004), and 
      the exercise test (standard mean difference 0.57, 95% CI 0.12, 1.02, P=0.01) all 
      showed significant differences. CONCLUSION: CSWT may offer beneficial effects to 
      patients with CAD, but more large-scale clinical studies are needed to further 
      verify its therapeutic effect.
FAU - Yang, Hai-Tao
AU  - Yang HT
AD  - Xinjiang Medical University First Affiliated Hospital Department of Cardiology 
      Urumchi People's Republic of China Department of Cardiology, First Affiliated 
      Hospital of Xinjiang Medical University, Urumchi, People's Republic of China.
FAU - Xie, Xiang
AU  - Xie X
AD  - Xinjiang Medical University First Affiliated Hospital Department of Cardiology 
      Urumchi People's Republic of China Department of Cardiology, First Affiliated 
      Hospital of Xinjiang Medical University, Urumchi, People's Republic of China.
FAU - Hou, Xian-Geng
AU  - Hou XG
AD  - Changji Hui Autonomous Prefecture People's Hospital Department of Cardiology 
      People's Republic of China Department of Cardiology, Changji Hui Autonomous 
      Prefecture People's Hospital, People's Republic of China.
FAU - Xiu, Wen-Juan
AU  - Xiu WJ
AD  - Xinjiang Medical University First Affiliated Hospital Department of Cardiology 
      Urumchi People's Republic of China Department of Cardiology, First Affiliated 
      Hospital of Xinjiang Medical University, Urumchi, People's Republic of China.
FAU - Wu, Ting-Ting
AU  - Wu TT
AD  - Xinjiang Medical University First Affiliated Hospital Department of Cardiology 
      Urumchi People's Republic of China Department of Cardiology, First Affiliated 
      Hospital of Xinjiang Medical University, Urumchi, People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20201001
PL  - Brazil
TA  - Braz J Cardiovasc Surg
JT  - Brazilian journal of cardiovascular surgery
JID - 101677045
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
SB  - IM
MH  - Angiotensin Receptor Antagonists
MH  - Angiotensin-Converting Enzyme Inhibitors
MH  - Canada
MH  - Cohort Studies
MH  - *Coronary Disease/therapy
MH  - *Extracorporeal Shockwave Therapy
MH  - High-Energy Shock Waves
MH  - Humans
MH  - Male
MH  - Percutaneous Coronary Intervention
MH  - Treatment Outcome
PMC - PMC7598952
OTO - NOTNLM
OT  - Confidence Intervals
OT  - Coronary Disease
OT  - Exercise Test
OT  - Extracorporeal Shockwave Therapy
OT  - Heart
OT  - Walking
COIS- No conflict of interest.
EDAT- 2020/10/30 06:00
MHDA- 2021/02/05 06:00
PMCR- 2020/09/01
CRDT- 2020/10/29 10:58
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2021/02/05 06:00 [medline]
PHST- 2020/10/29 10:58 [entrez]
PHST- 2020/09/01 00:00 [pmc-release]
AID - 10.21470/1678-9741-2019-0276 [doi]
PST - epublish
SO  - Braz J Cardiovasc Surg. 2020 Oct 1;35(5):741-756. doi: 
      10.21470/1678-9741-2019-0276.